Option Agreement

 
News Articles for Option Agreement top ^
Saturday, January 17, 2015, Medinah Minerals, Inc. (OTC PINK: MDMN) reports that its 100% owned Chilean subsidiary, Medinah Mining Chile (MMC) has now provided notice that the Option Agreement among the parties, Medinah Mining Chile (MMC), Compania Minera NUOCO Mining S.C.M. (NUOCO) and AURYN Mining Chile, SpA (“AURYN”), has now been formally signed and notarized under Chilean governing laws that grants to AURYN the ability to earn up to 85% of the shares of Compania Minera NUOCO Mining S.C.M. By Option Agreement, AURYN Mining Chile SpA can earn 60% of the NUOCO Company shares by completing a minimum of 5,000 meters of diamond drilling as well as conducting geophysical and geochemistry work matters.
Sign-up for Medinah Mining Chile Announces Formal Signing of an Option Agreement to Purchase All of the Shares of Compania Minera NUOCO Mining, S.C.M. investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
Sign-up for AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases investment picks
Medinah Minerals Inc. (OTC PINK: MDMN) reports that its 100% owned Chilean subsidiary, Medinah Mining Chile (MMC), has been presented with an option agreement proposing a purchase of Compania NUOCO Mining Chile S.C.M. properties by Medinah Mining Chile, as recommended by the Chilean firm C & R Consulting.
Sign-up for Medinah Mining Chile Announces Receipt of an Option Agreement Contract to Purchase All of Compania Minera NUOCO Mining, S.C.M. Mining Claims investment picks
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor --
Sign-up for Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.
Sign-up for Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Option Agreement
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Optimization Companies  |  Next: Option Contract